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1. Introduction
Ovarian cancer is the most lethal cause of gynecological cancer deaths in the developing
world and typically presents at an advanced stage when optimal debulking and platinum
based-chemotherapy remain the cornerstone of management. Unfortunately, despite fre‐
quent initial responses to chemotherapy, these tumors almost invariably relapse. Thanks to
recent large scale molecular profiling studies in ovarian cancer, such as the integrated ge‐
nomic analyses performed by the Cancer Genome Atlas (TCGA) network, significant head‐
way has been made in our understanding of the molecular pathogenesis of ovarian cancer1.
However these advances have failed to translate into meaningful clinical benefit for patients.
The only approved novel ‘targeted’ therapy to date in ovarian cancer is the anti-angiogenic
antibody, bevacizumab, for which reliable predictive markers still elude us.
With the possible exception of the p53 signaling network, the PI3K/Akt/mTOR cascade is
probably the most frequently altered signaling pathway in cancer, including ovarian cancer.
First generation inhibitors of mTOR have demonstrated anti-tumor activity and are current‐
ly approved for the treatment of renal, pancreatic, breast and some brain cancers. In addi‐
tion, a huge number of PI3K, Akt and second generation mTOR inhibitors are in early
clinical trials.
We propose to provide a brief overview of the PI3K/Akt/mTOR signaling network and dis‐
cuss the rationale for targeting this pathway in ovarian cancer. Preclinical data and results of
recent clinical trials will be presented. In addition, some of the challenges facing the devel‐
opment of these inhibitors in ovarian cancer will be discussed, such as the need for predic‐
tive markers and quality tumor samples, drug resistance, managing toxicity, as well as trial
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design considerations in order to optimize the development of novel therapies against the
PI3K pathway in ovarian cancer.
2. The PI3K/Akt/mTOR signaling pathway
The phophatidylinositol 3 Kinase (PI3K) pathway is a complex signaling network coordinat‐
ing a number of direct upstream inputs from growth factors (EGF, heregulin, TGF, and oth‐
ers), tyrosine kinase receptors (IGF1R, EGFR, HER2…) or other membrane receptors such as
Met as well as cross-talk with the Ras-Raf-Mek-Erk pathway via indirect input from Ras
(Figure 1). PI3K is composed of a p110 catalytic subunit and a p85 regulatory subunit. The
p110 subunit of PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to the ac‐
tive second messenger, PIP3 which recruits Akt to the plasma membrane, and results in a
conformational change and activation of PDK1 and Akt proteins. Akt is a serine threonine
kinase that regulates a huge number of downstream targets [2],[3], while the phosphatase
and tensin (PTEN) analog protein acts as an endogenous pathway repressor by de-phos‐
phorylating PIP3 back to PIP2. Akt controls critical cellular survival and metabolic processes
by influencing some of the following:
1. Via downstream regulation of p53, NFκΒ (nuclear factor κΒ) or CREB (cAMP response
element-binding protein), Akt promotes the transcription of genes involved in anti-
apoptotic and proliferative responses such as XIAP (X-linked inhibitor of apoptosis pro‐
tein), the apoptosis regulating protein Bcl-2, survivin and others[4].
2. Akt also phosphorylates proteins involved in cell cycle regulation and apoptosis thus
promoting cell cycle progression and survival:
a. Phosphorylation of GSK3 inhibits proteosomic degradation of cyclin D1,
b. Phosphorylation of the cyclin-dependent kinase (CDK) inhibitors p21 and p27 commits
them to nuclear export and removes their inhibitory effect on cyclin D and cyclin E,
c. Downregulation of the apoptotic effector, caspase 9.
3. In addition downstream signaling via mammalian target of rapamycin (mTOR) acti‐
vates two key substrates 4EBP1 and p70S6K resulting in increased translation of target
genes involved in angiogenesis (VEGF), or cell cycle progression (cyclin D1, c-Myc)[5].
In addition to activation via upstream input, the PI3K pathway can be ‘intrinsically’ activat‐
ed due to i) gain of function mutations or amplifications in the p110 subunit of PI3K
(PIK3CA), ii) mutations in the p85 subunit (PIK3R), iii) mutations or amplifications in one of
the Akt isoforms (AKT1, AKT2, AKT3), or iv) due to loss of its negative regulator, PTEN via
inactivating mutations, copy number loss or homozygous deletions.
While mTOR is probably the best described direct target of Akt, the mTOR complex is actually
composed of two components, the mTORC1-Raptor complex primary coordinator of transla‐
tional control via 4EBP1 and p70S6K[6]; and the mTORC2-Rictor complex whose function is
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less well described but likely regulates cell proliferation and survival in part by Akt activation
via phosphorylation at Serine 473[7]. Importantly mTORC1 is sensitive to inhibition by rapa‐
mycin, while mTORC2 is not. In the presence of selective mTORC1 inhibition, mTORC2 can ex‐
ert a positive feedback on Akt[8]. As discussed later, this positive feedback loop may have
important implications regarding the emergence of resistance to first generation mTOR inhibi‐
tors (rapalogs) that exclusively target mTORC1, with no effect on mTORC2.
 
Figure 1. The PI3K/Akt/mTOR signaling pathway. This pathway is up-regulated in a significant proportion of ovari‐
an cancers via either (i) direct upstream stimulation (growth factor receptors and their ligands), (ii) indirect activation
via cross-talk with the Ras pathway, or (iii) intrinsically via activating genetic alterations in PI3K or Akt, or via loss of
function in the tumor suppressor, PTEN.
3. Relevance of PI3K/Akt/mTOR signaling in ovarian cancer
The PI3K/Akt/mTOR pathway is frequently deregulated in ovarian cancer. Array Compara‐
tive Genomic Hybridization (aCGH) studies on 93 ovarian tumors have identified this path‐
way as the most frequently altered in ovarian cancer [9]. Copy gains in the genes encoding
both the p110α (PIK3CA) and p110β (PIK3CB) subunits of PI3K were associated with a poor
prognosis in patients with ovarian cancer. Expression levels of both p110α and pAkt were
analyzed in over 500 ovarian cancer tumors and associated with decreased survival. Activa‐
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tion of the pathway as measured by Akt or mTOR phosphorylation levels is almost ubiqui‐
tous in ovarian cancer and an independent negative prognostic marker [10-12].
Interestingly, the type of PI3K/Akt/mTOR molecular alteration appears to be histological
subtype specific (Table 1). There is mounting evidence that ovarian cancer is a highly hetero‐
geneous disease with marked differences in molecular profile, histology, prognosis and che‐
mosensitivity depending on the subtype [1],[13],[14]. The most common subtype (70%) high
grade serous ovarian cancer (HGSOC) is characterized by almost universal p53 mutations
(95-97% of cases) and marked genomic instability resulting in frequent somatic copy num‐
ber alterations (amplifications or deletions)[13]. In HGSOC, oncogenic mutations are rare,
but amplifications of the p110 subunit of PI3K (PIK3CA) have been described in 20% of cas‐
es, amplifications of one of the AKT isoforms (AKT 1, AKT2 or AKT3) occur in 15% to 20%,
while PTEN deletions have been described in 5%[15],[16] (Table 1). Finally RICTOR or RAP‐
TOR amplifications have also been reported [1]. Rare but potentially relevant mutations in
HGSOC include activating PIK3CA mutations (3%), or loss of function PTEN mutations (1%)
[17]. Mutations have also been described in the p85α subunit of PI3K (PIK3R1, 4%), resulting
in loss of its negative regulation on the p110 subunit and constitutive kinase activity[18]. In
summary, 40 to 50% of HGSOC may have constitutive PI3K signaling. In a significant pro‐
portion of HGSOC, hyperactive PI3K/Akt/mTOR pathway may also be attributable to up‐
stream deregulations in receptor tyrosine kinases (RTKs) or cross-talk with the
Ras/Mek/Mek/Erk pathway. Indeed, amplifications or mutations in RTKs such as ERBB3,
ERBB2, EGFR or IGF1R have been described with frequencies of 1% to 9% [1],[17]. Similarly,
the ras pathway is often altered in HGSOC by amplifications in KRAS (11%), MAPK (20%),
loss of the tumor suppressor NF1 (8%), or less frequent mutations in KRAS, NRAS, or BRAF.
Whereas individual mutations remain an infrequent event in HGSOC, they are much more
prevalent in the rarer subtypes such as low grade serous, mucinous, endometrioid or clear
cell ovarian cancer. For example, 20% of endometrioid and 35% of clear cell ovarian tumors
display PIK3CA mutations[19],[20]. In addition, while PTEN loss of function mutations are
rare in ovarian cancer in general, they are well documented in up to 20% of endometrioid
tumors and PTEN deletion occurs in 20% of endometrioid and clear cell ovarian cancers[21].
Low grade mucinous and serous subtypes do not tend to demonstrate intrinsic activation of
PI3K effectors, however they frequently exhibit KRAS mutations, or amplifications/muta‐
tions in ERBB2[22],[23].
Importantly intrinsic activation of the pathway (via PIK3CA mutations and PTEN loss) has
been shown to initiate ovarian tumors in mice and inhibition of PI3K/mTOR in these models
delayed tumor growth and prolonged survival, thus providing critical proof of concept for
the pathologic relevance of this pathway in OC and its potential as a therapeutic target[24],
[25]. Whether amplifications of pathway members actually activate PI3K signaling and con‐
fer comparable sensitivity to pathway inhibitors remains to be established. Similarly, while
cross-talk with Ras may result in PI3K activation, it is unlikely that this also results in PI3K
pathway dependence, however as discussed later, alterations in KRAS may be relevant with
regards to predicting benefit from dual PI3K-Ras inhibition.
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High grade serous ovarian cancer is exquisitely chemosensitive, with response rates to first-
line platinum-based chemotherapy of 75%, but almost invariably relapses with acquired re‐
sistance. The rarer subtypes tend to respond poorly to platinum chemotherapy with
response rates of only 15% to 30%. Thus both acquired and de novo chemotherapy resist‐
ance remains a significant clinical challenge in ovarian cancer. Increased phosphorylation of
mTOR has been described in cell lines with acquired cisplatin resistance, and Akt signaling
has been implicated in primary platinum resistance[12]. Inhibitors of Akt or mTOR were
shown to restore chemo-sensitivity in vitro and in xenograft models [26],[27]. These data
suggest a potential role for inhibitors of the PI3K pathway in modulating chemotherapy sen‐
sitivity and justify their use in combination with conventional cytotoxics.
Ovarian cancer
histological subtype
Intrinsic PI3K pathway
activation
PI3K activation via upstream
membrane RTKs
PI3K activation via cross-
talk with ras
High grade serous
(70%)
Amplifications:
PIK3CA (17-20%)
AKT1 (3%)
AKT2 (6-12%)
AKT3 (8%)
RICTOR (6%)
RAPTOR (4%)
Deletions:
PTEN (7%)
Amplifications:
ERBB3 (4%)
ERBB2 (3%)
IGF1R (4%)
Amplifications:
MAPK (25%)
KRAS (11%)
Deletions:
NF1 (8%)
Mutations:
PIK3CA (3%)
PIK3R1 (4%)
PTEN (1%)
Mutations:
EGFR (4-9%)
ERBB2 (1%)
Mutations:
NF1 (4%)
KRAS (1-5%)
NRAS (1%)
BRAF (1%)
Clear cell
Deletions
PTEN (20%)
Amplifications
ERBB2 (14%)
Mutations:
PIK3CA (33%)
Endometrioid
Deletions
PTEN (20%)
Mutations:
PIK3CA (20%)
PTEN (20%)
Mucinous Amplifications:ERBB2 (18%)
Mutations:
KRAS (40-60%)
Low grade serous Mutations:ERBB2 (15%)
Mutations:
KRAS (40%)
BRAF (1%)
Table 1. Molecular alterations according to ovarian cancer subtype that could contribute to PI3K pâthway activation
either directly (deregulated PI3K members) or indirectly via alterations in upstream RTKs or Ras pathway members.
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4. Results of clinical trials targeting the PI3K/Akt/mTOR pathway in
ovarian cancer
The frequent PI3K/Akt alterations demonstrated in vivo in tumors from patients with ovari‐
an cancer, combined with the evidence for dependence on this oncogenic pathway in pre‐
clinical models provide a robust biological rationale for investigating the benefit of targeting
PI3K, Akt or mTOR in ovarian cancer. However as detailed throughout this chapter, the in‐
trinsic complexity of this signaling network may limit the anti-tumor potential of inhibiting
a single effector along the pathway.
4.1. mTOR inhibitor monotherapy in ovarian cancer (Table 2)
The first inhibitors of the pathway to enter the clinic were rapamycin analogs that bind to the
FK506 binding protein-12 of the MTORC1 complex and prevent mTOR activity. Rapamycin
was used for years as an immunosuppressant to prevent rejection in solid organ transplants
and hematological malignancies; its toxicity profile is therefore well described with main side
effects consisting of edema, hypertension, renal toxicity, hematologic toxicity, and hypertrigly‐
ceridemia and hypercholesterolemia. In addition, rarer but potentially more concerning side
effects included interstitial lung disease, risk of secondary lymphoma, and reactivation of la‐
tent infections[28]. Rapamycin analogs with less immunosuppressive properties, such as tem‐
sirolimus, everolimus and ridaforolimus have shown activity in a number of tumor types.
A phase II trial of temsirolimus at a flat dose of 25mg IV weekly in patients with ovarian cancer
progressing after 1-3 previous regimens met its first stage response and PFS criteria at interim
analysis with three responses and seven PFS at 6 months and pursued accrual through the sec‐
ond stage[29]. At final analysis, with 54 evaluable patients, grade 3-4 toxicities were as expect‐
ed for mTOR inhibitors, mainly gastrointestinal (10%), metabolic (15%), and study drug was
discontinued in 6% for interstitial pneumonitis. Unfortunately, objective responses were only
seen in 9.3% (5/54) and 6 months PFS was 24% thus the study failed to meet its efficacy end‐
point. Exploratory analyses were conducted in order to identify potential predictive markers.
Phosphorylated-Akt, p-mTOR, p-p70-S6K, and cyclinD1 were measured in archival tumor
samples as surrogates for activation of the PI3K pathway; only cyclinD1 levels were weakly
correlated with PFS>6 months (r=0.28). The authors concluded that observed activity was in‐
sufficient to justify a phase III trial of temsirolimus in unselected patients with ovarian cancer.
As discussed later in the chapter; these negative results may be explained by i) the lack of pa‐
tient selection, ii) the cytostatic rather than cytotoxic effect of mTOR inhibitors (mTORi) and iii)
the fact that these agents may require combinations with chemotherapy or other targeted
agents to achieve a robust anti-tumor effect. The trial just fell short of its PFS efficacy endpoint
(>24% PFS at 6 months), had the study limited enrollment to clear cell and endometrioid histol‐
ogies known to show frequent PI3K alterations, the results may have been different.
4.2. mTOR inhibitors in combination with chemotherapy in ovarian cancer (Table 2)
Given the implication of mTOR and Akt in chemo-resistance and the preclinical studies sug‐
gesting an additive benefit with chemotherapy, studies have investigated mTORi-cytotoxic
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combinations. A phase I study of weekly topotecan (1mg/m2 days 1, 8 and 15) and temsiroli‐
mus 25mg days 1, 8, 15 and 22 on a 28 day schedule was conducted in 15 patients with gyne‐
cological malignancies including 7 patients with ovarian cancer. Dose limiting toxicities
were myelosuppression and although efficacy was not a primary objective, 8 of 11 patients
had stable disease at first evaluation and one patient with clear cell histology was still pro‐
gression free at 6 months[30].
A phase Ib dose escalation study of temsirolimus (T) and pegylated liposomal doxorubicin
(PLD) in advanced breast and gynaecological malignancies identified T 15mg and PLD
40mg/m2 as the maximum tolerated dose (MTD)[31]. The most frequent grade 3-4 adverse
events were fatigue (5%), nausea (16%), mucositis (21%), rash (11%) and hand-foot syn‐
drome (21%). The mean PFS was 4.9 months and the authors concluded that the combina‐
tion warranted further study.
Two other phase I studies of rapalogs in combination with chemotherapy (temsirolimus
plus carboplatin/paclitaxel[32] and everolimus plus weekly paclitaxel[33]) have been con‐
ducted with grade 3-4 neutropenia being the major DLT (at 89% and 56%, respectively) as
well as fatigue and mucositis. These studies included a small number of patients with ad‐
vanced ovarian cancer and responses were described (3 of 6 patients with ovarian cancer
had a PR to temsirolimus plus carboplatin and paclitaxel). However given the small num‐
bers and the combination with chemotherapy, no robust conclusions may be drawn regard‐
ing the added value of the mTOR inhibitor.
These early studies have begun to establish the feasibility and safety of mTORi-cytotoxic
combinations, randomized trials will be required to investigate efficacy. In the interim, a
number of non-randomized phase I and II studies are ongoing (Table 4). Given the heteroge‐
neity of ovarian cancer, non-randomized phase II studies may require a degree of patient se‐
lection by molecular alteration or even histology in order to enrich the trial for potential
responders and make the patient population more uniform with regards to natural disease
course and chemosensitivity. Indeed studies recruiting patients with both high and low
grade tumors with marked differences in tumor growth rates and responsiveness to chemo‐
therapy may mask any benefit from the addition of the mTOR inhibitor. For example, a
phase II trial of temsirolimus plus carboplatin and paclitaxel as adjuvant treatment is ongo‐
ing for patients with stage III or IV clear cell ovarian cancer (NCT01196429).
4.3. mTOR inhibitors in combination with anti-angiogenics in ovarian cancer (Table 2)
Finally, given the activity of VEGF inhibitors in ovarian cancer and the fact that downstream
mTOR targets include angiogenic genes, there is A biological rationale for using mTOR and
VEGF inhibitors in combination. A phase II trial of temsirolimus and bevacizumab in ovari‐
an cancer has been conducted[34]. Thirty one (31) patients were evaluable for toxicity and 25
for efficacy. Adverse events included fatigue, mucositis, hypertension and neutropenia. In
addition one grade 4 rash and 6% colonic perforations (2/31) were reported. While the con‐
firmed PR rate is only 12% in the first 25 evaluable patients (all in platinum-resistant pa‐
tients), the 6 months PFS rate of 56% (14/25) met efficacy criteria to justify progression to
second stage accrual. Updated results are awaited. It is noteworthy that the study only en‐
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rolled patients who had not been exposed to anti-angiogenics; the previously reported RR of
15-21% in early trials of bevacizumab monotherapy among heavily pretreated patients with
ovarian cancer raises the possibility that temsirolimus may be adding little anti-tumor effect
to bevacizumab alone[35],[36]. A randomized phase II study is ongoing comparing bevaci‐
zumab alone to bevacizumab and everolimus in patients with recurrent ovarian cancer
(NCT00886691, Table 4). Patients will be stratified according to their platinum-free interval
or prior treatment with bevacizumab. This study should provide valuable insight into the
potential additive benefit of this combinatorial strategy.
Reference Phase Treatment N, total
enrolled
N, ovarian
cancer
Selected toxicities Efficacy
Behbakht et al II Temsirolimus, 25mg IV D1,
8, 15, 22 Q28 days
54 54 G3-4 GI (10%),
metabolic (15%),
pulmonary (6%)
RR=9%
6 month
PFS=24%
Temkin et al I Temsirolimus IV 25mg D 1,
8, 15, 22 + topotecan
1mg/m2 IV D1, 8, 15 Q28
days
15 7 G3-4 neutropenia and
thrombocytopenia
RR=0
One SD for 6
months
Boers-
Sonderen et al
Ib MTD= temsirolimus IV 15mg
D1, 8, 15, 22 + PLD IV
40mg/m2 D1 Q28 days
20 NA G3-4 fatigue (5%),
nausea (16%), mucositis
(21%), vomiting (16%),
rash (11%), hand-foot
syndrome (21%)
NA
Kollsmannberg
er et al
I MTD= temsirolimus IV 25mg
D1 and 8 + carbo AUC5 IV
D1 + Pac IV 175mg/m2 D1
Q 21 days
39 6 G3-4 neutropenia
(89%),
thrombocytopenia
(21%), pulmonary (5%)
RR= 50% (3/6)
SD=50% (3/6)
Campone et al I Everolimus PO 30mg daily +
Pac 80mg/m2 D 1, 8, 15 Q
28 days
16 3 G3 neutropenia, anemia,
thrombocytopenia,
mucositis, fatigue
NA
Morgan et al II Temsirolimus IV 25mg D 1,
8, 15, 22 + Bev 10mg/kg D1
and 15 Q 28 days
31 31
evaluable
for toxicity
and 25
evaluable
for efficacy
G3-4 fatigue (13%),
mucositis (13%), HTN
(6%), neutropenia
(10%), rash (3%),
colonic perforation (6%)
RR=12%
6month PFS
56%
Abbreviations: N: number of patients; IV: intravenous; D: day; Q: every; G3-4: grade 3-4; RR: response rate; PFS: pro‐
gression-free survival; SD: stable disease; MTD: maximum tolerated dose; PLD: pegylated liposomal doxorubicin; NA:
information not available; carbo: carboplatin; pac: paclitaxel; PO: per os.
Table 2. Completed clinical trials of mTOR inhibitors in ovarian cancer
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While the evidence for clinical activity of mTOR inhibitors in ovarian cancer remains quite lim‐
ited, especially compared to endometrial cancer where efficacy has been more encouraging, a
number of phase II trials of mTOR inhibitors alone or in combination with conventional cyto‐
toxics or targeted therapies are currently ongoing. These should help clarify the role mTOR in‐
hibitors may have in the management of patients with ovarian cancer (Table 4).
4.4. Akt inhibitors
Targeting Akt upstream from mTOR may produce a more effective knock-down of signal
transduction and a number of Akt inhibitors have therefore been generated. These include
ATP-competitive inhibitors, allosteric inhibitors, peptide-based inhibitors and lipid-based
inhibitors (reviewed in Stronach et al[37]). Akt inhibitors are still in early stages of clinical
development and two compounds have been specifically tested in ovarian cancer (Table 3).
The most mature inhibitor in clinical development is the lipid-based inhibitor, perifosine, it
interferes with the cell membrane recruitment of Akt (thus preventing activation). However
early data in phase I and II trials in other tumor types were disappointing with frequent gas‐
trointestinal toxicity and a lack of meaningful activity[38]-[41]. Given the suggestion that the
narrow therapeutic window of perifosine may limit its clinical usefulness, combination trials
with conventional cytotoxics have been conducted in order to improve the therapeutic in‐
dex. Preclinical studies have shown that perifosine inhibited ovarian cancer cell prolifera‐
tion, motility and angiogenesis and potentiated paclitaxel sensitivity in vitro and in vivo[42],
[43]. On this basis, a phase I trial of perifosine and docetaxel in platinum and taxane resist‐
ant ovarian cancer was conducted[42]. Perifosine was given at a loading dose of 100mg ev‐
ery 6 hours for 4 doses followed by a daily dose according to dose level (50, 100 or 150mg
daily) in combination with docetaxel 75mg/m2 day 1 every 3 weeks. Twenty one patients
were enrolled including 11 at the MTD level of perifosine 150mg. No DLTs were observed,
frequent adverse events included nausea, vomiting, anorexia, constipation and fatigue. With
regards to efficacy at the MTD (N=11), there was one PR in an endometrioid ovarian cancer
with a loss of function PTEN mutation (R130Q) and one SD maintained for 4 months in a
PI3K mutated clear cell tumor. Two other patients without apparent PI3K alterations ach‐
ieved SD while two patients with KRAS mutations progressed quickly. The investigators al‐
so performed pharmacodynamic studies using reverse phase protein array (RPPA) to detect
changes in total and phosphorylated markers in pre-treatment versus day 7 tumor biopsies
and functional imaging studies using FDG-PET scans. Bcl2 and ERK2 levels were increased
by treatment suggesting that the low response rate may be in part explained by perifosine
induced increases in alternate signalling pathways. However FDG-PET responses at one
week correlated with inhibition of S6 phosphorylation raising the possibility that FDG-PET
may serve as an early surrogate indicator of Akt inhibition.
GSK795 is an oral ATP-competitive pan-Akt inhibitor in early stages of development and a
small phase I pharmacodynamic and pharmacokinetic study was conducted in order to
characterize the relationship between AKT inhibition by GSK795 and downstream effects in
patients with advanced platinum resistant ovarian cancer[44]. Twelve patients were enrol‐
led. The only toxicities were grade 2 anorexia (18%) and vomiting (18%). FDG metabolism
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decreased in the majority of tumors but there was no dose response relationship. Among 5
patients treated at the higher dose levels, paired pre- and post-treatment tumor biopsies
demonstrated downregulation in pAkt and in the tumor proliferative marker, Ki67. Two pa‐
tients have achieved >6 months PFS with objective tumor regressions of 26% and 11%, re‐
spectively.
In  addition  to  the  aforementioned  inhibitors,  Akt  isoform  specific  inhibitors  are  being
developed,  however  the  distinct  functions  of  each  of  these  isoforms  and  their  rele‐
vance  to  different  tumor  types  or  individual  tumor  genetic  background  is  still  poorly
understood.  Studies  of  AKT isoform knockouts  provide  some insight  into  their  relative
roles:  AKT1  loss  is  associated  with  impaired  fetal  development  and  increased  fetal
mortality;  AKT2 loss  leads  to  diabetes  and AKT3 loss  results  in  defective  central  nerv‐
ous system development[45].
Reference Phase Treatment N, total
enrolled
N,
ovarian
cancer
Selected toxicities Efficacy
Fu et al I MTD Perifosine orally
150mg/day + docetaxel,
75mg IV D1 Q21 days
21 21 Nausea, vomiting,
anorexia, fatigue
At MTD
(N=11) PR in
1 PTEN null,
SD 3/11.
Gungor et al I GSK795 25, 50 or 75mg
orqlly/day
12 12 G2 anorexia (18%),
vomiting (18%)
16% SD for
6 mo (2/12)
with tumor
shrinkage of
26% and
11%
Table 3. Completed clinical trials of Akt inhibitors in ovarian cancer
4.5. PI3K inhibitors
The PI3K inhibitors, LY290002 and wortmannin have been used for years as tools in preclin‐
ical experiments to demonstrate the biological relevance of PI3K and explore its potential as
a therapeutic target in cancer. However, the micromolar IC50 (50% inhibitory concentration)
and off-target effects of these agents have limited their clinical applicability. Less toxic PI3K
inhibitors are just entering phase II stages of clinical development (reviewed in Kurtz et
al[46]). BKM120 is an oral selective PI3K inhibitor with an IC50 for the PI3K kinase of 35nM.
A dose escalation phase I trial has shown that the drug is well tolerated at the MTD of
100mg once a day with rash, hyperglycemia, diarrhea and mood alterations in over a third
of patients[47]. BKM120 demonstrated dose dependent inhibition of FDG activity and
downregulation in p-S6 in skin biopsies. The only response was in a KRAS mutated breast
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cancer patient, and 7 patients had stable disease for more than 8 months. Five of these 7 pa‐
tients had either PTEN loss or PI3K mutation. GDC0941 is an oral selective class I PI3K in‐
hibitor that showed evidence of clinical activity in 3 patients enrolled in a phase I trial,
including one ovarian cancer (PTEN negative) patient who remained on study for 5 months
with a FDG-PET response, >50% decrease in pS6 staining in paired biopsies, and 80% de‐
crease in CA-125[48]. XL147 is another selective PI3K inhibitor which was well tolerated in a
phase I trial with rash as the main DLT. An associated trial of XL147 in combination with
carboplatin and paclitaxel demonstrated that the combination was feasible with no evidence
of PK interactions or overlapping toxicities and dose expansion cohorts are ongoing in ovar‐
ian cancer[49].
5. Challenges of PI3K/Akt/mTOR pathway inhibitors
Despite a strong preclinical rationale, clinical trials of novel agents targeting the PI3K/Akt/
mTOR pathway in ovarian cancer have been disappointing. Given the complexity and re‐
dundancy of the PI3K signaling network, combined targeting may be required. The fact that
all the trials conducted to date enrolled an unselected patient population may have diluted
objective activity in a subset. It is therefore crucial that efforts are made to uncover resist‐
ance mechanisms, develop rationale combinatorial strategies, identify predictive biomark‐
ers, and explore novel trial designs.
5.1. Resistance
5.1.1. Feedback loops via MTORC2 or IRS1
Compensatory feedback loops may allow escape from blockade of a single effector of the
pathway. Early on, paradoxical increases in pAkt were identified in preclinical models and
in tumors from patients treated with mTOR inhibitors8. As illustrated in Figure 2, rapalogs
suppress MTORC1 but do not affect the other subunit of mTOR, MTORC2. MTORC2 is a
positive regulator of Akt, and selective inhibition of MTORC1 results in compensatory in‐
crease in Akt phosphorylation at Serine 473[50]. Rapalog-induced rebound Akt activation
has been proposed as one of the mechanisms accounting for resistance to first generation in‐
hibitors in the clinic. In addition, although the function and downstream effectors of
MTORC2 are less well described, it is reasonable to expect that complete abrogation of the
whole mTOR complex may be required to achieve a robust anti-tumor effect. As a result,
mTORC1/mTORC2 dual inhibitors have been developed such as DS3078a, INK128,
AZD8055, OSI027 and AZD2014 (reviewed in [51]).
Another postulated compensatory escape route from mTOR inhibition is via insulin growth
factor 1 receptor (IGF1R, see Figure 2)[52]. Insulin receptor substrate-1 is normally under
basal negative regulation via phosphorylation by mTOR; mTOR inhibition prevents IRS-1
phosphorylation thus allowing IRS-1 to complex with IGF1R and promote Akt signaling[53]
thereby generating another positive feedback loop accounting for resistance.
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Figure 2. Proposed mechanisms accounting for resistance to inhibitors of the PI3K pathway. (1) Selective block‐
ade of MTORC1 by rapalogs increases MTORC2 and results in positive feedback activation of pAkt. (2) Inhibition of
mTOR removes the basal inhibition of IRS1, now free to bind to and activate IGF1R and promote PI£K activation. (3) In
the presence of constitutive activation of KRAS, abrogation of the PI3K pathway alone does not inhibit cancer cell
growth. (4) A dysfunctional apoptotic pathway (high bcl2, high survivin...) may lead to resistance to the pro-apoptotic
effects of PI3K apthway inhibitors. (5) One downstream effect of Akt inhibition is cell cyle arrest via increase in the cdk
inhibitors, p21 or p27; p27 low tumors may be resistant to PI3K pathway inhibitor induced cell cycles arrest.
5.1.2. The Ras pathway: KRAS/BRAF mutations and compensatory increases in Erk signaling
Interactions with parallel pathways may also allow escape from PI3K inhibition. Akt has
been shown to be phosphorylated via cross-talk with Ras. Thus, in KRAS mutant tumors
primarily driven by a constitutively upregulated Ras pathway, PI3k pathway inhibitors
alone are unlikely to be effective. This hypothesis is supported by studies demonstrating
that KRAS or BRAF mutated tumors are insensitive to mTOR inhibitors. Using a panel of
cell lines including ovarian cancer, PI3K mutated tumors were shown to be sensitive, while
dual PI3K and KRAS or BRAF mutated tumors were resistant to everolimus[54]. Important‐
ly, they also demonstrated that knock-down of the KRAS mutation in these cells restored ev‐
erolimus sensitivity in vitro and in vivo. In the presence of KRAS or BRAF mutations,
tumors may exhibit ‘oncogenic addiction’ to an alternate survival pathway, e.g. Ras-Raf-
Mek-Erk. This illustrates the fact that sensitivity to PI3K transduction inhibitors may require
not only pathway activation but also demonstration of pathway dependence.
In addition to reactivating Akt, rapalogs have been reported to cause treatment induced in‐
creases in Mek/Erk signalling. In mice models and human tumors, everolimus increased
Erk1/2 activation in post treatment tumor samples, suggesting the existence of crosstalk be‐
tween the PI3K/mTOR and Mek/Erk signal transduction cascades[55]. Selective targeting of
one pathway may simply result in compensatory upregulation in the other, and vice versa.
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5.1.3. Dysfunctional apoptotic machinery
Even in tumor types such as renal cell or pancreatic neuroendocrine cancers where mTOR
inhibitors have demonstrated sufficient clinical benefit to justify FDA approval, objective tu‐
mor responses are sporadic[56]. Some researchers have hypothesized that tumor shrinkage
in response to mTOR inhibitors requires a functional apoptotic machinery. Majumder et al
demonstrated that rapamycin-resistant SKOV3 ovarian cells have an activated PI3K path‐
way but upregulated levels of the anti-apoptotic protein, bcl2, and bcl2 knock-down using
siRNA restored rapamycin sensitivity[57]. In line with this preclinical data, the Phase I trial
of the Akt inhibitor perifosine reported compensatory increases in bcl2 in post treatment tu‐
mor biopsies[42].
5.1.4. Cell cycle dependent kinase (cdk) inhibitors
One of the major anti-tumor effects of PI3K blockade is to activate the cdk inhibitors p27 and
p21, allow their nuclear translocation where they interact with, and inhibit cdks, thereby
promoting cell cycle arrest. p27-null cells are resistant to rapamycin in vitro, some therefore
postulate that tumors that have very low levels of p27 may therefore be less responsive to
PI3K/Akt inhibition[58].
5.2. Combinatorial strategies
Given the presence of redundant pathways and the adaptive capacity of cancer cells, drug
combinations are increasingly being investigated in an effort to abrogate both primary and
acquired resistance to PI3K pathway inhibitors. Different approaches include targeting the
same pathway at different levels (vertical combinations) or aiming for different pathways
(horizontal combinations).
5.2.1. Vertical combinations
With membrane growth factor receptor inhibitors
Activation of the PI3K pathway can be attributable to upstream activation via membrane re‐
ceptor kinases, and preclinical data suggest that concurrent inhibition of mTOR and EGFR
may result in synergistic anti-tumor effect. Studies are investigating the benefit of dual
mTOR/EGFR blockade[59]. A completed phase I trial showed that the combination of evero‐
limus, bevacizumab and panitumumab was well tolerated, and three patients with ovarian
cancer achieved prolonged disease control for 11 to >40 months[59]. In addition, mTOR in‐
hibition may induce IRS1 expression and promote Akt activation via IGF1R thus attenuating
the anti-tumor effects of rapalogs[60]. The addition of IFG1R antibodies to mTOR inhibitors
has been shown to improve growth inhibition in vitro[52]. Studies investigating concurrent
IGF1R/mTOR targeting have shown that treatment is feasible with an acceptable toxicity
profile and encouraging activity in other tumor types[61] and studies using this approach
are ongoing in ovarian cancer (Table 4).
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Treatment type Phase Experimental
treatment
Prior treatment Selection
criteria
(biomarker vs
allcomers)
Secondary endpoints Clinical
trial.gov
identifier
PI3K inhibitor I BKM120 +
Olaparib (PARP
inhibitor)
First line
platinium-based
CT
All comers MTD for the combination, safety, PK, efficacy. PD
markers of PI3K inhibition, determination of BRCA1
IHC, BRCA1 promoter hypermethylation and
BRCA1/2 somatic mutation status
NCT01623349
AKT inhibitor I GSK2141795 Not specified All comers PK and PD by FDG/PET NCT01266954
II MK-2206 Platinum
resistant
P13K or AKT
mutation or
low PTEN
expression
RR, PFS and OS, toxicities of MK-2206, explore the
association between select biomarkers and
response to MK-2206, to explore the development
of feedback loop activation and target inhibition
with MK-2206.
NCT01283035
I Perifosine +
docetaxel
Not specified All comers Tumor response NCT00431054
I/II GSK2110183 +
carbo+pac
Platinum
resistant, "/>2
prior lines of CT
All comers Phase I : safety and tolerability NCT01653912
Phase II : overall RR
1st generation
MTOR inhibitor
I Sirolimus +
ALVAC(2)-NY-
ESO-1 vaccine
Not specified Tumor
expression of
NY-ESO-1 or
LAGE-1
Safety, effectiveness of sirolimus on enhancing
vaccine efficacy, antibody titers, NY-ESO-1 specific
CD8+ and CD4+ frequency and function, PFS.
NCT01536054
II Temsirolimus Taxane based
treatment, <3
prior CT
All comers PFS, rate and duration of stable diseases, cancer
antigen 125 (for ovarian cancer), overall survival,
safety and toxicity, quality of life, rate and duration
of stable diseases
NCT01460979
II Temsirolimus +
carbo + pac
Refractory to
standard
treatment
All comers MTD, toxicity, RR, PK. NCT00408655
I Everolimus + PLD
+ carbo
One prior
platinum/
taxane-CT
All comers MTD for the combination, safety/tolerability, anti-
tumor activity
NCT01281514
I Ridaforolimus +
carbo + pac
<4 prior CT lines All comers MTD, preliminary efficacity, toxicity NCT01256268
II Adjuvant
Temsirolimus +
carbo + pac
followed by
maintenance
temsirolimus
First line Clear cell
histology only
PFS at 12 months, median PFS, OS, toxicity and RR.
mTOR signaling pathway by IHC.
NCT01196429
1st generation
mTOR inhibitor in
combination with
II Everolimus +
bevacizumab
Previously
treated
All comers PFS at 6 months, complete response + partial
response + stable disease
NCT01031381
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Treatment type Phase Experimental
treatment
Prior treatment Selection
criteria
(biomarker vs
allcomers)
Secondary endpoints Clinical
trial.gov
identifier
antiangiogenic
therapy
II Temsirolimus +
bevacizumab
Previously
treated
All comers RR, PFS at 6 months, OS, duration of response, TTP.
No specific biomarker objectives specified but
blood and tumor collected on all
NCT01010126
I Temsirolimus +
Cediranib (VEGFR
2 inhibitor)
<2 prior line of
CT for recurrent
disease
All comers MTD , response rate, clinical benefit NCT01065662
II Everolimus +/-
bevacizumab
randomised trial
Platinum-based
CT.
Stratification
according to
platinum
resistant vs. not,
measurable
disease vs. not
and prior
bevacizumab vs.
not
All comers PFS, tolerability, OS, RR, CA-125 response. NCT00886691
mTOR or Akt
inhibitor + IGF1R
inhibitor
IB MK-2206 (Akt
inhibitor) or
ridaforolimus +
IGF1R Ab
(dalotuzumab),
non randomized
study
Previously
treated.
Platinum
resistance
required for
MK-2206 arm
All comers Number of participants with dose limiting toxicities,
number of participants whose best response is a
partial response (PR) or complete response (CR)
NCT01243762
mTOR inhibitor in
combination with
Notch pathway
inhibitor
I Ridaforolimus +
MK-0752
<3 prior CT lines All comers Number of participants with dose limiting toxicities,
AUC for the ridaforolimus + MK-0752 doublet
NCT01295632
Abbreviations: PARP : poly-ADP-ribose polymerase ; CT : chemotherapy ; MTD : maximum tolerated dose, PK : phar‐
macokinetic ; PD : pharmacodynamic ; BRCA : breast cancer susceptibility gene ; IHC : immunohisotchemistry ; FDG/
PET : fluorodeoxyglucose positron emission tomography ; RR : response rate ; PFS : progression-free survival ; OS : over‐
all survival ; carbo : carboplatin ; pac : paclitaxel ; NY-ESO-1 : cancer-testis antigen-1 ; LAGE-1 : cancer-testis antigen-2 ;
PLD : pegylated liposomal doxorubicin ; TTP : time to progression ; VEGFR : vascular endothelial growth factor recep‐
tor ; IGF1R : insulin-like growth factor receptor ; AUC : area under the curve.
Table 4. Ongoing trials of PI3K pathway inhibitors in ovarian cancer
Combined PI3K-mTOR or Akt-mTOR inhibition
As previously discussed, positive feedback loops generated by selective mTOR inhibition
may result in paradoxical activation of Akt via mTORC2 and account for early resistance.
The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Biological Rationale and Therapeutic Opportunities
http://dx.doi.org/10.5772/54170
289
Dual MTORC1 and MTORC2 inhibitors have therefore been developed and shown to result
in greater anti-tumor activity than rapalogs in preclinical studies[62]. Another strategy in‐
volves co-targeting mTOR as well as upstream PI3K in order to overcome the positive feed‐
back loops via Akt. In addition, simultaneous targeting of several effectors of the PI3K
pathway may improve the likelihood of completely shutting down the signaling cascade. A
combination of everolimus and the PI3K inhibitor, PI-103 blocked rebound rapalog induced
Akt activation and resulted in greater cell cycle arrest than either treatment alone in ovarian
cancer cells[63]. NVP-BEZ235 is a novel agent that is both an ATP-competitive PI3K inhibi‐
tor and an inhibitor of both mTORC1 and mTORC2. Studies in ovarian cancer cell lines and
mouse models have suggested that this drug caused cell cycle arrest and apoptosis, and pro‐
longed survival of mice with established ovarian tumors[64]. A phase I trial of ridaforolimus
with the Akt inhibitor MK2206 is ongoing and a dose expansion cohort in ovarian cancer is
planned (NCT01295632). Other studies are exploring the benefit of inhibiting further down‐
stream effectors such as p70S6 in combination with everolimus (NCT01115803).
5.2.2. Horizontal combinations
With Mek inhibitors
Given the evidence that oncogenic activation of the ras pathway may be associated with re‐
sistance to mTOR inhibitors even in the presence of PI3K oncogenic mutations, targeting
both PI3K and Ras pathways simultaneously is worthy of investigation. In a mouse model
of ovarian cancer driven by PTEN loss and KRAS mutation, simultaneous blockade of both
PI3K and Mek signalling using pharmacological inhibitors resulted in significant tumor re‐
gressions and prolonged survival compared to monotherapy[65]. A phase I study compar‐
ing the tolerability and efficacy of dual PI3K and Mek targeting to either treatment alone
showed that the combination significantly increased the risk of Grade 3-4 toxicity from 18%
to 54% (p=0.001), but all patients with alterations in the PI3K pathway and a KRAS or BRAF
mutation had tumor regressions with dual targeting[66].
With chemotherapy
One of the earliest explored strategy has been the combination of novel inhibitors with che‐
motherapy. There has been the theoretical concern that the cytostatic effects of these drugs
may in fact antagonize the cell cycle dependent effects of chemotherapy. Preclinical studies
in ovarian cancer have indeed suggested that PI3K inhibitor-induced G1 arrest undermined
the cytotoxic effects of agents such as cisplatin, paclitaxel, gemcitabine and topotecan that
are primarily effective in the S or G2 phase of the cell cycle[67]. However preliminary data
from non-randomized studies of mTOR inhibitors in combination with chemotherapy have
reported objective response rates comparable to those expected for chemotherapy alone,
thus providing indirect evidence for a lack of antagonism. Randomized studies will be re‐
quired to rule out any antagonism between PI3K inhibitors and conventional cytotoxics.
With anti-angiogenics
Pro-angiogenic factors such as HIF1α and VEGF are downregulated by inhibition of PI3K
signaling. This may explain the activity of mTOR inhibitors in HIF1α-driven clear cell renal
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cancer. Given the putative anti-angiogenic effects of PI3K pathway inhibitors and the known
activity of the VEGF antibody, bevacizumab in ovarian cancer, there is a rationale for target‐
ing multiple angiogenic regulators at once in an effort to shut down angiogenesis complete‐
ly. In fact, clear cell ovarian cancers with their reported angiogenic signature and increased
HIF1α signaling[68] may be particularly suited to a therapeutic strategy combining tradi‐
tional anti-angiogenics with PI3K pathway inhibitors.
5.3. Biomarkers
In light of the heterogeneity of ovarian cancer, predictive as well as pharmacodynamic
(demonstrating target downregulation) biomarkers are desperately needed in order to select
patients most likely to respond. In addition biomarkers would be useful to identify the sub‐
set of patients who may benefit from specific combinations. One question is whether sensi‐
tivity can be predicted on the basis of activation status of pathway members.
5.3.1. Constitutive PI3K activity: PIK3CA mutations and PTEN loss of function
The main intrinsic effectors of the pathway that have been studied in preclinical and clinical
models have been PTEN loss, and PIK3CA activating mutations. Early studies in cell lines
including ovarian cancer demonstrated greater anti-proliferative activity of PI3K pathway
inhibitors in PTEN-null or PIK3CA mutated cells[69]-[71], Di Nicolantonio et al, showed in
cell lines and in 43 patient tumor samples that PIK3CA mutations sensitized cancer cells to
everolimus, but co-existing KRAS or BRAF mutations predicted resistance[54]. More recent
clinical and preclinical studies have reported contradictory correlations between PI3K muta‐
tions or PTEN loss and response to inhibitors[72],[73]; in particular, a significant number of
PI3K mutated tumors fail to respond, while a proportion of tumors lacking PI3K and PTEN
alterations respond. This is in contrast to the much stronger association between activating
mutations and response to other targeted agents such as EGFR, BRAF or ALK inhibitors.
Studies in tumor types with frequent PTEN mutations, such as melanoma have not demon‐
strated significant responses to mTOR inhibitors suggesting that patient selection on the ba‐
sis of PTEN loss alone may not identify responders[74]. In a pooled analysis of 3 trials of
mTOR inhibitors in endometrial cancers, MacKay et al found no correlation between
PIK3CA mutation or PTEN loss and response[75]. However a recent report by Janku and
colleagues suggested that PI3K mutations did preferentially identify responders[76]. They
conducted mutational analyses on 140 patients with breast and gynecological malignancies
(including 60 with ovarian cancer) enrolled in phase I trials of PI3K/Akt/mTOR inhibitors.
They demonstrated that the response rate was higher among patients with PIK3CA mutated
tumors (RR=30% versus 10%). However these results should be interpreted in light of the
fact that all responders were included in a trial of temsirolimus, bevacizumab and liposomal
doxorubicin. Given the known activity of bevacizumab and liposomal doxorubicin in ovari‐
an cancer and the fact that half the responding patients had never been previously exposed
to liposomal doxorubicin, mutations may simply correlate with prognosis, or with an im‐
proved response to treatment in general.
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In conclusion, if trials of PI3K/mTOR inhibitors had limited enrolment to PTEN null or PI3K
mutated tumors a significant proportion of responding patients would have been missed. In
light of the imperfect association between PI3K mutations or PTEN loss and response to
PI3K pathway inhibitors, most ongoing trials are enrolling an unselected patient population;
unfortunately, most of these studies do not appear to be collecting archival tumor samples
for detailed molecular analyses (Table 4).
5.3.2. pAkt and stathmin
The level of phosphorylated Akt has been identified as a read-out for activation of the PI3K
pathway and thus a potential biomarker for responsiveness to PI3K inhibitors. An in vitro
and in silico study using a panel of cell lines and xenograft models treated with PI3K path‐
way inhibitors showed that pAkt correlated with efficacy, and KRAS or BRAF mutations
with resistance; neither PTEN loss nor PIK3CA mutations correlated with response[77].
Udai et al analyzed PI3K signaling output in patient tumor samples by measuring phos‐
phorylation of 3 effectors downstream of PI3K, ie pAkt, p p70S6K and pGSK3beta[78]. No
correlation was found between the presence of genomic alterations in PI3K or PTEN and ac‐
tivation of the pathway as measured by phosphorylated downstream targets. In a study of
17 well-characterized ovarian cancer cell lines, the majority failed to respond to Akt inhibi‐
tors despite Akt phosphorylation[79]. A high level of pAkt may not only reflect PI3K path‐
way intrinsic activation, but also result from cross-talk with Ras or other upstream signals.
In addition to being a non-specific measure of PI3K signal transduction, pAkt is a labile
phosphorylated tumor marker, its stability is affected by pre-analytical factors such as tissue
acquisition, ischemic time and fixation method[80],[81], In an effort to identify more stable
biomarkers, Saal et al developed a gene expression signature of PI3K pathway activation
and Stathmin, a regulator of microtubule dynamics was an accurate marker of the gene sig‐
nature. Stathmin can be easily measured by immunohistochemistry and is increasingly be‐
ing used as a surrogate marker for activation of the PI3K pathway[82].
5.3.3. KRAS/BRAF
As previously discussed a number of preclinical studies have demonstrated that KRAS and
BRAF mutations confer resistance to inhibitors of the PI3K pathway[54],[77]. Intringingly, in
a pooled molecular analysis of patients treated with PI3K/Akt/mTOR inhibitors in phase I
trials, Janku et al reported 2 objective responses in patients with co-existing PI3K and KRAS
or BRAF mutation[76]. Genomic analyses of tumors and cell lines has established that a sub‐
set of ovarian cancers have co-existing Ras and PI3K/Akt amplifications or mutations. This
easily identifiable subset may benefit from coordinated inhibition of both pathways, and a
trial combining a Mek inhibitor with a PI3K/mTOR inhibitor in ovarian cancer patients har‐
boring KRAS/BRAF and PI3K/Akt genomic alterations is warranted.
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6. Practical issues: Samples and trial design
6.1. Access to quality ovarian cancer samples
As the data to date suggest that there is insufficient evidence to select patients for trials
of  PI3K inhibitors on the basis  of  specific  molecular alterations,  it  is  imperative that fu‐
ture  trials  enrolling  unselected patient  populations  include parallel  biological  studies  in
an  effort  to  uncover  candidate  biomarkers.  Biological  assays  must  be  reproducible,  ro‐
bust and require access to high quality tumor samples.  As such, pre-analytical  variables
must be controlled for as much as possible by following standardized sample collection,
fixation,  processing  and  storage  procedures.  When  dealing  with  paraffin-embedded  tis‐
sue,  markers  of  the  PI3K  Akt  pathway  may  be  particularly  susceptible  to  artefactual
loss[80]. In fact,  the optimal fixative for in depth genomic analyses is unlikely to be for‐
malin, and may therefore require a shift in routine practice from paraffin to fresh frozen
or RNAlater for sample storage.
6.2. Access to post-treatment samples
6.2.1. At relapse
It  is  likely that  clonal  evolution and treatment selection pressure will  lead to important
genomic and/or phenotypic modifications in the tumor in the interval between diagnosis
and relapse.  An increasing number of  phase I  and II  trials  are  therefore  requesting op‐
tional biopsies of metastatic disease and the vast majority of patients are willing to con‐
sent  this  procedure.  A  study  of  patients  enrolled  in  phase  I  trials  at  our  institution
revealed that  84% of  patients  who were proposed optional  tumor biopsies consented to
the procedure,  including sequential  pre-  and post-treatment biopsies[85].  All  procedures
were  performed  using  an  18-gauge  needle  under  ultrasound  or  computed  tomography
scanning and were associated with low minor complication rates (9/145 tumor biopsies).
In  70%  of  the  cases  the  biopsy  met  quality  criteria  for  ancillary  molecular  (RNA  and
DNA) analyses. Access to samples from relapsed disease is likely to be particularly rele‐
vant to high grade ovarian cancer, where the initial disease is exquisitely chemosensitive
and repeat  profiling of  the chemoresistant  recurrence may reveal  a  completely different
molecular profile.
6.2.2. Residual disease post-chemotherapy
The  molecular  characterization  of  ovarian  cancer  clones  surviving  after  chemotherapy
could identify targets for novel agents designed to eradicate chemoresistant residual dis‐
ease. As discussed above, the combination of PI3K/Akt/mTOR inhibitors with chemother‐
apy  may  not  be  optimal  because  of  the  risk  of  cumulative  toxicities  as  well  as  the
theoretical  risk that these inhibitors may antagonize the cytotoxic effects  of  chemothera‐
py. A more attractive approach may be sequential, where primarily chemosensitive ovar‐
ian cancer is  treated with chemotherapy followed by PI3K inhibitors if  indicated by the
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molecular  profile  of  the  residual  resistant  clones.  Although  recent  trials  using  such  an
approach with erlotinib or olaparib after response to platinum based treatment were dis‐
appointing, neither trial selected the maintenance treatment on the basis of the profile of
residual disease.
6.3. Surrogate tissue
Any effort to sample relapsed disease in ovarian cancer patients invariably faces the chal‐
lenge of access to tumor. Recurrences tend to be limited to the abdominal cavity with diffuse
carcinomatosis which can be difficult to biopsy safely. This is a critical need for more easily
accessible surrogate tumor samples which would allow for serial tumor sampling through‐
out the disease course, to identify both predictive and pharmacodynamic markers. Possibili‐
ties include circulating tumor cells, ascites and circulating DNA.
Serial sampling of circulating tumor cells (CTCs) has been shown to provide useful prognos‐
tic and/or predictive information in a number of tumor types such as breast and prostate
cancer[86],[87]. In the temsirolimus trial, CTCs were detected in 45% of patients before cycle
1 and found to correlate weakly with progressive disease, however no significant change in
CTC levels were observed with treatment[29].
Udai et al demonstrated the feasibility of profiling the PI3K pathway from ascites in patients
with advanced ovarian cancer: they successfully measured PI3K and PTEN mutations, am‐
plifications and losses as well as PI3K signaling output in ascitic samples by ELISA for phos‐
phorylated proteins[78]. Finally, cancer mutations have been identified by deep sequencing
of circulating plasma DNA from patients with advanced ovarian cancer, providing another
example of a non-invasive “liquid biopsy”[88].
1) Standardized quality ovarian cancer sample collection protocols at diagnosis and surgery optimized for
comprehensive molecular studies.
2) Sequential biopsies for post-treatment/resistant tumor molecular profiling.
3) Studies investigating the feasibility and translational research value of surrogate tissue samples: ascites, circulating
tumor cells, circulating DNA
Table 5. Sample-related considerations to enhance the development of PI3K pathway inhibitors in ovarian cancer
6.4. Novel trial designs
Conventional endpoints such as RECIST response may not be appropriate for inhibitors of
the PI3K pathway that may result in disease stabilization rather than objective tumor shrink‐
age. Single arm phase II trials offer little data regarding activity of a novel drug: patient
numbers are small, heterogeneous and comparisons with historical controls are intrinsically
unreliable. A number of subtle deviations from traditional trial designs could help improve
the likelihood that novel PI3K inhibitors make a successful transition from preclinical testing
through early and late phase trials. Various strategies are outlined in table 6.
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∙ Randomized placebo controlled phase II trials instead of single arm phase II.
∙ Randomized discontinuation design: After an initial run-in phase where all patients receive the experimental agent,
patients with stable disease are randomized to placebo versus continued drug. This model may be particularly suited
to slower growing Type I ovarian cancers where the distinction between treatment induced disease stabilization and
natural disease course may be difficult to make.
∙ When evaluating tumor response on imaging, percentage tumor shrinkage as a continuous variable could be used,
rather than categorical RECIST where an arbitrary cut-off of 30% decrease to define response may be more suited to
conventional cytotoxics.
∙ Metabolic response on functional imaging by FDG/PET.
∙ Using each patient as internal control for evidence of drug activity: the ratio of time to progression (TTP) on
experimental drug to TTP on last treatment (TTPn+1/TTPn), where TTPn+1/TTPn ≥1.3 would suggest drug activity[89];
Table 6. Suggested modifications to the traditional trial design adapted to testing PI3K pathway inhibitors and other
novel therapies
7. Conclusion
The PI3K pathway is  emerging as an important  and viable therapeutic  target.  However
evidence  for  efficacy  in  ovarian  cancer  remains  limited  and  predictive  biomarkers  to
identify  the  patients  most  likely  to  benefit  from  this  approach  are  desperately  needed.
Given the complexicity of the PI3K pathway and its  cross-talk with other signaling net‐
works, inhibiting a single member of the pathway may be insufficient to abrogate onco‐
genic  signaling  and  result  in  meaningful  tumor  control.  A  number  of  resistance
mechanisms to PI3K pathway inhibitors have been identified. Primary resistance may be
attributable to co-existing KRAS or BRAF mutations; therefore concurrent PI3K and Mek
inhibition in dual PI3K/KRAS mutated ovarian cancer may be worthy of investigation. In
addition,  treatment  induced  compensatory  increases  in  alternate  pathways  (via  IGF1R,
MTORC2/Akt  and  others)  may  allow  escape  from  selective  mTOR  targeting;  response
could be improved by appropriately designed combinatorial strategies. This suggests that
abrogating adaptive escape pathways will  require truly individualized treatment,  select‐
ed on the basis of on-treatment tumor biopsies to identify the culprit compensatory path‐
ways.  A  number  of  trials  are  ongoing  exploring  the  benefit  of  combinations,
unfortunately few are including correlative biological studies. Finally, for decades, ovari‐
an cancer was treated as a uniform disease, a greater understanding of the biology of ep‐
ithelial  ovarian  tumors  has  encouraged  the  initiation  of  a  few  histology-specific  trials.
The successful transition of novel PI3K pathway inhibitors from bench to the bedside of
patients with ovarian cancer will  depend on a greater integration of translation research
in trial development. Efforts must be made to include comprehensive molecular profiling
both at  baseline  and sequentially  throughout  the  disease  course,  and studies  investigat‐
ing the usefulness of novel surrogate tumor markers such as ascites or circulating DNA
will likely be essential.
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